BRAF and melanoma: In addition, functional in vitro studies conducted on melanoma models showed that FDA-approved BRAF inhibitors vemurafenib and dabrafenib are only effective against class 1 monomer-type mutations (V600 mutations); whereas, class 2 is sensitive to novel panRAF-inhibitor (LY3009120) or MEK-inhibitors (trametininb) and class 3 to EGFR-inhibitor (cetuximab and panitumumab) and RTKs-inhibitors (dasatinib) [34, 71, 128].